Torrent Pharmaceuticals to Acquire JB Chemicals: A Landmark Deal in India's Pharma Industry

Torrent Pharmaceuticals aims to complete the acquisition of a majority stake in JB Chemicals for Rs 19,500 crore, bolstering its presence in the Indian pharmaceutical market. The merger offers strategic access to JB's chronic segment brands, operational synergies, and international market opportunities.

Torrent Pharmaceuticals is set to reshape the Indian pharmaceutical landscape with its Rs 19,500-crore acquisition of JB Chemicals. The deal, expected to be completed in 15-18 months, marks the second largest transaction in the domestic pharmaceutical space, following Sun Pharma's acquisition of Ranbaxy in 2015.

The acquisition includes an initial purchase of a 46.39% stake from promoters and a further 2.80% stake from certain employees. This will be followed by an open market offer for an additional 26% in compliance with listing norms. The strategic acquisition grants Torrent access to JB Pharma's leading chronic segment brands and opens opportunities in new therapeutic areas like ophthalmology.

Following regulatory approvals from the Competition Commission of India and other authorities, JB Pharma will merge with Torrent. Shareholders of JB Pharma will receive Torrent shares in exchange. This move is anticipated to enhance Torrent's market share and diversify its capabilities in contract development and manufacturing, strengthening its position in both local and international markets.

(With inputs from agencies.)